Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRT umbrella trial with randomized phase III comparison of high-dose chemotherapy versus focal radiotherapy consolidation
2018-003335-29Phase 3Active
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- May 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of thiotepa, carboplatin, cyclophosphamide, etoposide, ifosfamide and 4 more in Atypical teratoid rhabdoid tumor (ATRT) (2 arms), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Overall survival. Started May 2019; status: active.
02
Drugs
thiotepacarboplatincyclophosphamideetoposideifosfamide
03
Conditions
Atypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on 2018-003335-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003335-29.